Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.

Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D.

Oncotarget. 2018 Feb 15;9(24):16932-16950. doi: 10.18632/oncotarget.24524. eCollection 2018 Mar 30.

PMID:
29682195
2.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Apr 13. doi: 10.1097/CAD.0000000000000629. [Epub ahead of print]

PMID:
29659371
3.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Apr 9. doi: 10.1097/CAD.0000000000000628. [Epub ahead of print]

PMID:
29634490
4.

Infrastructure and distributed learning methodology for privacy-preserving multi-centric rapid learning health care: euroCAT.

Deist TM, Jochems A, van Soest J, Nalbantov G, Oberije C, Walsh S, Eble M, Bulens P, Coucke P, Dries W, Dekker A, Lambin P.

Clin Transl Radiat Oncol. 2017 May 19;4:24-31. doi: 10.1016/j.ctro.2016.12.004. eCollection 2017 Jun.

5.

Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study.

Leijenaar RT, Bogowicz M, Jochems A, Hoebers FJ, Wesseling FW, Huang SH, Chan B, Waldron JN, O'Sullivan B, Rietveld D, Leemans CR, Brakenhoff RH, Riesterer O, Tanadini-Lang S, Guckenberger M, Ikenberg K, Lambin P.

Br J Radiol. 2018 Mar 22:20170498. doi: 10.1259/bjr.20170498. [Epub ahead of print]

PMID:
29451412
6.

A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.

Jochems A, El-Naqa I, Kessler M, Mayo CS, Jolly S, Matuszak M, Faivre-Finn C, Price G, Holloway L, Vinod S, Field M, Barakat MS, Thwaites D, de Ruysscher D, Dekker A, Lambin P.

Acta Oncol. 2018 Feb;57(2):226-230. doi: 10.1080/0284186X.2017.1385842. Epub 2017 Oct 14.

PMID:
29034756
7.

Optimal concentration range of golimumab in patients with axial spondyloarthritis.

Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15.

PMID:
28980904
8.

Radiomics: the bridge between medical imaging and personalized medicine.

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S.

Nat Rev Clin Oncol. 2017 Dec;14(12):749-762. doi: 10.1038/nrclinonc.2017.141. Epub 2017 Oct 4. Review.

PMID:
28975929
9.

Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries.

Jochems A, Deist TM, El Naqa I, Kessler M, Mayo C, Reeves J, Jolly S, Matuszak M, Ten Haken R, van Soest J, Oberije C, Faivre-Finn C, Price G, de Ruysscher D, Lambin P, Dekker A.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):344-352. doi: 10.1016/j.ijrobp.2017.04.021. Epub 2017 Apr 24.

10.

Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.

Even AJG, Reymen B, La Fontaine MD, Das M, Jochems A, Mottaghy FM, Belderbos JSA, De Ruysscher D, Lambin P, van Elmpt W.

Acta Oncol. 2017 Nov;56(11):1591-1596. doi: 10.1080/0284186X.2017.1349332. Epub 2017 Aug 25.

PMID:
28840770
11.

Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms.

Zindler JD, Jochems A, Lagerwaard FJ, Beumer R, Troost EGC, Eekers DBP, Compter I, van der Toorn PP, Essers M, Oei B, Hurkmans CW, Bruynzeel AME, Bosmans G, Swinnen A, Leijenaar RTH, Lambin P.

Radiother Oncol. 2017 May;123(2):189-194. doi: 10.1016/j.radonc.2017.02.006. Epub 2017 Feb 23.

PMID:
28237400
12.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
13.

Distributed learning: Developing a predictive model based on data from multiple hospitals without data leaving the hospital - A real life proof of concept.

Jochems A, Deist TM, van Soest J, Eble M, Bulens P, Coucke P, Dries W, Lambin P, Dekker A.

Radiother Oncol. 2016 Dec;121(3):459-467. doi: 10.1016/j.radonc.2016.10.002. Epub 2016 Oct 28.

14.

Big Data in radiation therapy: challenges and opportunities.

Lustberg T, van Soest J, Jochems A, Deist T, van Wijk Y, Walsh S, Lambin P, Dekker A.

Br J Radiol. 2017 Jan;90(1069):20160689. doi: 10.1259/bjr.20160689. Epub 2016 Dec 8.

15.

Decision support systems for personalized and participative radiation oncology.

Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RT, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EE, Even AJ, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RT, Zegers CM, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S.

Adv Drug Deliv Rev. 2017 Jan 15;109:131-153. doi: 10.1016/j.addr.2016.01.006. Epub 2016 Jan 14. Review.

PMID:
26774327
16.

The Dutch Melanoma Treatment Registry As Blueprint For Using Registry Data To Improve Health Care Decision Making.

Franken M, Leeneman B, Schouwenburg M, Jochems A, Wouters M, Van den Eertwegh F, Haanen J, Van der Hoeven K, Uyl-de Groot C.

Value Health. 2015 Nov;18(7):A491. doi: 10.1016/j.jval.2015.09.1361. Epub 2015 Oct 20. No abstract available.

17.

Improved Survival In Patients With Advanced Melanoma In Real-World Clinical Practice: First Results Of The Dutch Melanoma Treatment Registry.

Leeneman B, Franken MG, Jochems A, Schouwenburg MG, Wouters MW, Van den Eertwegh AJ, Haanen JB, Van der Hoeven KJ, Uyl-de Groot CA.

Value Health. 2015 Nov;18(7):A440-1. doi: 10.1016/j.jval.2015.09.1079. Epub 2015 Oct 20. No abstract available.

18.

Improved Survival With Ipilimumab In Patients With Advanced Melanoma In Real-World Clinical Practice: First Results Of The Dutch Melanoma Treatment Registry.

Leeneman B, Franken MG, Jochems A, Schouwenburg MG, Wouters MW, Van den Eertwegh AJ, Haanen JB, Van der Hoeven KJ, Uyl-de Groot CA.

Value Health. 2015 Nov;18(7):A440. doi: 10.1016/j.jval.2015.09.1077. Epub 2015 Oct 20. No abstract available.

19.

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.

de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR.

BMC Cancer. 2015 Oct 5;15:652. doi: 10.1186/s12885-015-1663-5.

20.

A robust in vivo-like persistent firing supported by a hybrid of intracellular and synaptic mechanisms.

Jochems A, Yoshida M.

PLoS One. 2015 Apr 22;10(4):e0123799. doi: 10.1371/journal.pone.0123799. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0130237.

21.

Transition between encoding and consolidation/replay dynamics via cholinergic modulation of CAN current: A modeling study.

Saravanan V, Arabali D, Jochems A, Cui AX, Gootjes-Dreesbach L, Cutsuridis V, Yoshida M.

Hippocampus. 2015 Sep;25(9):1052-70. doi: 10.1002/hipo.22429. Epub 2015 Mar 26.

PMID:
25678405
22.

Comparison of properties of medial entorhinal cortex layer II neurons in two anatomical dimensions with and without cholinergic activation.

Yoshida M, Jochems A, Hasselmo ME.

PLoS One. 2013 Sep 12;8(9):e73904. doi: 10.1371/journal.pone.0073904. eCollection 2013.

23.

Cholinergic receptor activation supports persistent firing in layer III neurons in the medial entorhinal cortex.

Jochems A, Reboreda A, Hasselmo ME, Yoshida M.

Behav Brain Res. 2013 Oct 1;254:108-15. doi: 10.1016/j.bbr.2013.06.027. Epub 2013 Jun 26.

24.

Persistent firing supported by an intrinsic cellular mechanism in hippocampal CA3 pyramidal cells.

Jochems A, Yoshida M.

Eur J Neurosci. 2013 Jul;38(2):2250-9. doi: 10.1111/ejn.12236. Epub 2013 May 8.

PMID:
23651161
25.

Long-lasting intrinsic persistent firing in rat CA1 pyramidal cells: a possible mechanism for active maintenance of memory.

Knauer B, Jochems A, Valero-Aracama MJ, Yoshida M.

Hippocampus. 2013 Sep;23(9):820-31. doi: 10.1002/hipo.22136. Epub 2013 Jun 3.

PMID:
23609880
26.

Cholinergic modulation of the CAN current may adjust neural dynamics for active memory maintenance, spatial navigation and time-compressed replay.

Yoshida M, Knauer B, Jochems A.

Front Neural Circuits. 2012 Mar 15;6:10. doi: 10.3389/fncir.2012.00010. eCollection 2012.

Supplemental Content

Loading ...
Support Center